Scarica l'app Stockscreener
60.13
2.00%
-1.23
Dopo l'orario di chiusura:
60.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GH Giù?
Forum
Previsione
Precedente Chiudi:
$61.36
Aprire:
$61.41
Volume 24 ore:
2.88M
Relative Volume:
1.18
Capitalizzazione di mercato:
$7.50B
Reddito:
$692.26M
Utile/perdita netta:
$-512.41M
Rapporto P/E:
-14.18
EPS:
-4.24
Flusso di cassa netto:
$-274.36M
1 W Prestazione:
-10.81%
1M Prestazione:
+30.24%
6M Prestazione:
+40.95%
1 anno Prestazione:
+147.14%
Intervallo 1D:
$58.67
$61.95
Intervallo di 1 settimana:
$57.50
$68.00
Portata 52W:
$20.14
$68.00
Guardant Health Inc Stock (GH) Company Profile
Nome
Guardant Health Inc
Settore
Industria
Telefono
855-698-8887
Indirizzo
3100 HANOVER STREET, PALO ALTO
Confronta GH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
60.13 | 7.65B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
492.60 | 184.84B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
200.21 | 142.52B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
642.99 | 51.24B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
128.75 | 36.42B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
187.68 | 31.29B | 15.70B | 1.24B | 2.01B | 6.91 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-28 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-24 | Ripresa | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-11-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Iniziato | Craig Hallum | Buy |
| 2022-10-06 | Iniziato | Stephens | Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-04-28 | Ripresa | BTIG Research | Buy |
| 2022-02-24 | Reiterato | Canaccord Genuity | Buy |
| 2022-02-24 | Reiterato | Citigroup | Buy |
| 2022-02-24 | Reiterato | Cowen | Outperform |
| 2022-02-24 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-24 | Reiterato | SVB Leerink | Outperform |
| 2022-02-24 | Reiterato | Stifel | Buy |
| 2022-02-24 | Reiterato | Wells Fargo | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-11 | Iniziato | Stifel | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-06-12 | Iniziato | BTIG Research | Buy |
| 2020-02-21 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-08-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-04-16 | Iniziato | Canaccord Genuity | Buy |
| 2019-04-10 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Reiterato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | JP Morgan | Overweight |
| 2018-10-29 | Iniziato | William Blair | Outperform |
Mostra tutto
Guardant Health Inc Borsa (GH) Ultime notizie
New Blood Test Algorithm Shows Sensitivity, Specificity in CRC Screening - CancerNetwork
Live market analysis of Guardant Health Inc.July 2025 Opening Moves & Weekly High Return Stock Forecasts - Newser
Is Guardant Health Inc. a turnaround storyEarnings Recap Summary & Weekly Watchlist for Hot Stocks - خودرو بانک
Growth Review: How does Guardant Health Inc. score in quality rankingsJuly 2025 PreEarnings & Fast Gain Stock Trading Tips - خودرو بانک
What to expect from Guardant Health Inc. in the next 30 daysMarket Performance Report & Community Shared Stock Ideas - Newser
Is Guardant Health Inc. showing signs of accumulationBull Run & Free Weekly Watchlist of Top Performers - Newser
Guardant Health reports positive clinical readout update for Shield algorithm - Yahoo Finance
Signal strength of Guardant Health Inc. stock in tech scannersJuly 2025 Patterns & Smart Swing Trading Techniques - Newser
Detecting price anomalies in Guardant Health Inc. with AIOptions Play & Real-Time Volume Spike Alerts - Newser
Multi asset correlation models including Guardant Health Inc.2025 Support & Resistance & Safe Swing Trade Setups - Newser
Volume spikes in Guardant Health Inc. stock – what they meanJuly 2025 Sentiment & Community Trade Idea Sharing - Newser
Guardant Health Surges to $280M in Volume as Stock Plunges 5.69% to 378th Rank - AInvest
The Oncology Institute, Inc. shares rise 1.70% intraday after Guardant Health's positive clinical readout update for its Shield™ blood test. - AInvest
Guardant Health shares drop 9% after data release for Shield colorectal cancer screening test. - AInvest
Guardant Health Stock Falls on Colorectal Cancer Test UpdateNews and Statistics - IndexBox
Why Guardant Health (GH) Shares Are Plunging Today - Yahoo Finance
Guardant Health: BTIG Maintains Buy, Raises PT to $70 from $65 - AInvest
Why IBD 50's Guardant Health Just Tumbled, Breaking A 67% Monthlong Run - inkl
Guardant Health stock falls 8% despite Evercore ISI’s positive outlook - Investing.com
Guardant Health Updates Results for Shield Blood Test in Colorectal Cancer - MarketScreener
Guardant Health Plunges 11.05% Amid Insider Trading Concerns - AInvest
Guardant drops after trial data for cancer test (GH:NASDAQ) - Seeking Alpha
What drives Guardant Health Inc.’s stock priceJuly 2025 Rallies & Risk Controlled Swing Alerts - خودرو بانک
Guardant Health’s Shield blood test shows 84% sensitivity for colorectal cancer - Investing.com
Guardant Health Updates Shield Blood-Based Colorectal Cancer Screening Test with New Algorithm - AInvest
Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test - Yahoo Finance
Liquid Biopsy Market to Hit USD 24.70 Billion by 2033 | Key Players - openPR.com
When is the best time to exit Guardant Health Inc.Earnings Overview Report & Daily Technical Stock Forecast Reports - Newser
How to read the order book for Guardant Health Inc.July 2025 Catalysts & Fast Exit Strategy with Risk Control - Newser
What to do if you’re stuck in Guardant Health Inc.Insider Buying & Fast Gain Stock Trading Tips - Newser
How volatile is Guardant Health Inc. stockPortfolio Risk Summary & Low Risk Investment Opportunities - خودرو بانک
Technical signs of recovery in Guardant Health Inc.2025 Price Momentum & High Return Stock Watch Alerts - Newser
Is it too late to sell Guardant Health Inc.IPO Watch & Advanced Swing Trade Entry Plans - Newser
Joyce, Guardant Health director, sells $6,584 in shares - Investing.com
Using flow based indicators on Guardant Health Inc.2025 Investor Takeaways & Long-Term Safe Investment Plans - Newser
Joyce, Guardant Health director, sells $6,584 in shares By Investing.com - Investing.com UK
Guardant Health Director Sells 100 Shares at $65.84 on 2025-09-02 - AInvest
Liquid Biopsy in Cancer Diagnostics Market to Witness Robust ~17% CAGR Expansion by 2032 | DelveInsight - Barchart.com
Is Guardant Health Inc. stock ready for a breakoutPortfolio Performance Summary & Stepwise Trade Execution Plans - Newser
Analyzing recovery setups for Guardant Health Inc. investors2025 Top Gainers & Risk Managed Trade Strategies - Newser
How to recover losses in Guardant Health Inc. stockPortfolio Update Summary & Stepwise Swing Trade Plans - Newser
Guardant Health Inc. stock daily chart insightsPortfolio Profit Report & Safe Capital Growth Tips - Newser
Is It Too Late to Sell Guardant Health Inc.2025 Big Picture & Daily Technical Forecast Reports - beatles.ru
Automated trading signals detected on Guardant Health Inc.Weekly Gains Report & Capital Efficiency Focused Strategies - Newser
Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands - Eastern Progress
Will Guardant Health Inc. stock split in the near futureMarket Weekly Review & Weekly Momentum Picks - Newser
Is GH's Q1 2025 forecast achievable? - AInvest
Advanced analytics toolkit walkthrough for Guardant Health Inc.Analyst Downgrade & Weekly Top Gainers Alerts - Newser
Cyted Health’s $44M Series B: A Strategic Bet on Early Cancer Detection and Global Expansion - AInvest
Liquid Biopsy Market Trends and Industry Forecast to 2030 - GlobeNewswire
Liquid Biopsy Market Trends and Industry Forecast to 2030 Featuring Strategic Analysis of Natera, Guardant Health, Myriad Genetics, Illumina, and Roche Among Others - Yahoo Finance
Guardant Health Inc Azioni (GH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):